Rhumbline Advisers Has $279,000 Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Rhumbline Advisers boosted its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 17.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 56,874 shares of the company’s stock after purchasing an additional 8,619 shares during the quarter. Rhumbline Advisers owned 0.14% of Zevra Therapeutics worth $279,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of ZVRA. Armistice Capital LLC acquired a new position in Zevra Therapeutics during the 4th quarter valued at $1,755,000. Vanguard Group Inc. raised its stake in Zevra Therapeutics by 3.6% during the 1st quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock valued at $9,883,000 after purchasing an additional 58,866 shares during the last quarter. Retirement Planning Co of New England Inc. raised its stake in Zevra Therapeutics by 11.0% during the 1st quarter. Retirement Planning Co of New England Inc. now owns 430,193 shares of the company’s stock valued at $2,495,000 after purchasing an additional 42,766 shares during the last quarter. Mystic Asset Management Inc. raised its stake in Zevra Therapeutics by 15.4% during the 1st quarter. Mystic Asset Management Inc. now owns 266,297 shares of the company’s stock valued at $1,545,000 after purchasing an additional 35,514 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in Zevra Therapeutics during the 4th quarter valued at $177,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Thomas Anderson acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, July 16th. The shares were purchased at an average price of $6.81 per share, with a total value of $68,100.00. Following the acquisition, the director now directly owns 20,000 shares in the company, valued at $136,200. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have purchased a total of 22,000 shares of company stock valued at $140,340 in the last 90 days. 2.40% of the stock is currently owned by insiders.

Zevra Therapeutics Stock Down 5.3 %

ZVRA opened at $6.92 on Friday. The firm’s 50-day simple moving average is $7.16 and its 200-day simple moving average is $5.76. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00. Zevra Therapeutics, Inc. has a twelve month low of $3.89 and a twelve month high of $8.95. The firm has a market cap of $364.13 million, a price-to-earnings ratio of -5.13 and a beta of 1.94.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. The firm had revenue of $4.45 million during the quarter, compared to the consensus estimate of $4.08 million. During the same period in the previous year, the company posted ($0.15) EPS. Equities research analysts anticipate that Zevra Therapeutics, Inc. will post -1.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on ZVRA shares. HC Wainwright upped their target price on shares of Zevra Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, September 20th. Roth Mkm increased their price objective on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday. Maxim Group increased their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday. William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Finally, JMP Securities initiated coverage on shares of Zevra Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $17.00 price objective for the company. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $21.00.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.